IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
IceCure Medical announced that Legacy Health’s Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center has joined the company’s ChoICE post-market study of ProSense® cryoablation for low-risk breast cancer. The company says the FDA-approved study is expected to enroll approximately 400 patients across up to 30 U.S. sites and names Dr. Nathalie Johnson as a co-primary investigator for the Legacy site.